Xoma Royalty Corp (XOMA)

Jan 08, 2026

Is XOMA Royalty Corporation stock a defensive play in 20252025 Investor Takeaways & Reliable Price Breakout Signals - ulpravda.ru

Jan 08, 2026

Jan 06, 2026

Will XOMA Royalty Corporation (X0M1) stock profit from fiscal stimulus2026 world cup usa national team quarterfinals top scorers counter attacking tactical prediction breakdown - ulpravda.ru

Jan 06, 2026

Jan 04, 2026

Takeda, XOMA ink new royalty agreement; amend existing deal - MSN

Jan 04, 2026

Jan 02, 2026

Xoma royalty corp sees sale of $16.98 million in stock by investors - MSN

Jan 02, 2026

Jan 02, 2026

Antibody Development Company Cleared to Pursue Royalties for Tremfya, Judge Rules - Law.com

Jan 02, 2026

Jan 01, 2026

Can XOMA Royalty Corporation stock double in next 5 yearsTechnical Analysis Insights & Free Trend Following Techniques - bollywoodhelpline.com

Jan 01, 2026

Dec 31, 2025

Leerink Partners reiterates Outperform rating on XOMA stock at $45 target - Investing.com India

Dec 31, 2025

Dec 31, 2025

XOMA and Takeda execute royalty sharing transaction - The Pharma Letter

Dec 31, 2025

Dec 30, 2025

Takeda regains majority of mezagitamab royalty interest from XOMA - Investing.com

Dec 30, 2025

Dec 30, 2025

XOMA Royalty: Entitled to Payments Associated - 富途牛牛

Dec 30, 2025

Dec 30, 2025

Drug royalties reshuffled as XOMA trades part of one for nine experimental drugs - Stock Titan

Dec 30, 2025

Dec 30, 2025

XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Up 31.7% in December - MarketBeat

Dec 30, 2025

Dec 26, 2025

XOMA Royalty (XOMAO) Stock Analysis Report | Financials & Insights - Benzinga

Dec 26, 2025

Dec 23, 2025

XOMA Royalty Declares Quarterly Preferred Stock Dividends - Sahm

Dec 23, 2025

Dec 22, 2025

XOMA Royalty Corporation Announces Cash Dividends for Preferred Stockholders - Quiver Quantitative

Dec 22, 2025

Dec 21, 2025

Institutional Owners May Consider Drastic Measures as XOMA Royalty Corporation's (NASDAQ:XOMA) Recent US$57m Drop Adds to Long-term Losses - 富途牛牛

Dec 21, 2025

Dec 21, 2025

XOMA Royalty (NASDAQ:XOMA) shareholders have earned a 13% CAGR over the last three years - Yahoo Finance

Dec 21, 2025

Dec 20, 2025

Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps - MSN

Dec 20, 2025

Dec 20, 2025

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - RTTNews

Dec 20, 2025

Dec 19, 2025

Can XOMA Royalty Corporation stock deliver strong Q4 earningsRate Hike & Smart Investment Allocation Insights - Улправда

Dec 19, 2025

Dec 16, 2025

Generation Bio is latest Mass. biotech to be acquired by Xoma - The Business Journals

Dec 16, 2025

Dec 16, 2025

Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced - Investing.com

Dec 16, 2025

Dec 16, 2025

‘Zombie’ biotech buyer Xoma to acquire Generation Bio - Yahoo Finance

Dec 16, 2025

Dec 15, 2025

XOMA Royalty Corporation to Acquire Generation Bio Co. in Cash Transaction with Milestone and Royalty Opportunities - Quiver Quantitative

Dec 15, 2025

Dec 15, 2025

XOMA Royalty Enters into Agreement to Acquire Generation Bio - GlobeNewswire

Dec 15, 2025

Dec 15, 2025

Investors Don't See Light At End Of XOMA Royalty Corporation's (NASDAQ:XOMA) Tunnel - simplywall.st

Dec 15, 2025

Dec 15, 2025

FY2025 EPS Estimates for XOMA Royalty Reduced by Analyst - MarketBeat

Dec 15, 2025

Dec 13, 2025

BVF Inc. IL Has $65.28 Million Stock Position in XOMA Royalty Corporation $XOMA - MarketBeat

Dec 13, 2025

Dec 12, 2025

XOMA stock maintains Buy rating at Benchmark despite partner’s trial setback - Investing.com

Dec 12, 2025

Dec 12, 2025

Xoma announces closing of transactions to acquire Lava Therapeutics - MSN

Dec 12, 2025

Dec 12, 2025

XOMA: HC Wainwright Maintains Buy Rating, Lowers Price Target to $97 | XOMA Stock News - GuruFocus

Dec 12, 2025

Dec 11, 2025

Leerink Partners lowers XOMA stock price target on RZ358 trial failure By Investing.com - Investing.com South Africa

Dec 11, 2025

Dec 11, 2025

HC Wainwright & Co. Maintains XOMA Royalty (XOMA) Buy Recommendation - Nasdaq

Dec 11, 2025

Dec 11, 2025

Why two Bay Area companies' stocks tumbled on a drug's clinical failure - The Business Journals

Dec 11, 2025

Dec 11, 2025

Leerink Partners lowers XOMA stock price target on RZ358 trial failure - Investing.com Canada

Dec 11, 2025

Dec 11, 2025

XOMA stock price target lowered to $97 by H.C. Wainwright - Investing.com Australia

Dec 11, 2025

Dec 11, 2025

XOMA: Leerink Partners Lowers Price Target, Reiterates Outperfor - GuruFocus

Dec 11, 2025

Dec 11, 2025

Why Is XOMA Royalty Stock Sinking Thursday?Rezolute (NASDAQ:RZLT), XOMA Royalty (NASDAQ:XOMA) - Benzinga

Dec 11, 2025

Dec 09, 2025

LUCID CAPITAL MARKETS Initiates Coverage of XOMA Royalty (XOMA) with Buy Recommendation - Nasdaq

Dec 09, 2025

Dec 09, 2025

Lucid Capital Markets initiates coverage on XOMA stock with Buy rating - Investing.com Canada

Dec 09, 2025

Dec 09, 2025

XOMA Royalty (XOMA): New Buy Rating Initiated by Lucid Capital M - GuruFocus

Dec 09, 2025

Dec 08, 2025

XOMA Royalty Corp CEO Owen Hughes Acquires 100,000 Depositary Shares - TradingView — Track All Markets

Dec 08, 2025

Dec 06, 2025

Mural Oncology Announces Sanction of the Scheme by the High Court - 富途牛牛

Dec 06, 2025

Dec 06, 2025

XOMA (NASDAQ:XOMAO) Trading 0.8% Higher – Time to Buy? - Defense World

Dec 06, 2025

Dec 06, 2025

XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share - Investing.com Nigeria

Dec 06, 2025

Dec 06, 2025

XOMA Royalty completes acquisition of Mural Oncology By Investing.com - Investing.com Nigeria

Dec 06, 2025

Dec 05, 2025

Xoma announces closing of transaction to acquire Mural Oncology - TipRanks

Dec 05, 2025